Abstract: Buparlisib (BKM120) is an orally bioavailable, pan-class I phosphoinositide 3-kinase (PI3K) inhibitor that has been extensively investigated for the treatment of breast cancer. The PI3K/AKT/mTOR signaling pathway is frequently hyperactivated in breast cancer, contributing to tumor progression and resistance to endocrine and HER2-targeted therapies. Buparlisib exerts its effects by competitively binding to the ATP-binding site of PI3K, thereby inhibiting the production of the secondary messenger PIP3 and blocking downstream signaling. Clinical trials, including the pivotal BELLE-2 and BELLE-3 studies, have demonstrated that combining buparlisib with endocrine therapy (e.g., fulvestrant) significantly improves progression-free survival in patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer, particularly those harboring PIK3CA mutations. However, its clinical utility is substantially limited by a challenging toxicity profile, including hepatotoxicity, hyperglycemia, and severe psychiatric adverse events due to its ability to cross the blood-brain barrier. Consequently, while buparlisib provided proof-of-principle for PI3K inhibition in breast cancer, future perspectives emphasize the development of isoform-specific inhibitors and novel combination strategies to enhance efficacy and minimize adverse effects.
1. Introduction
Breast cancer is a leading cause of cancer-related mortality in women, characterized by diverse molecular subtypes and genomic alterations [1][3]. The phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is one of the most frequently dysregulated signaling networks in breast cancer, particularly in hormone receptor-positive (HR+) tumors [2][6]. Aberrant activation of this pathway—often driven by PIK3CA mutations, PTEN loss, or HER2 amplification—promotes tumor cell survival, proliferation, and resistance to standard therapies such as endocrine therapy and HER2-targeted agents [2][4][6]. To overcome this resistance, targeting the PI3K pathway has emerged as a critical therapeutic strategy. Buparlisib (BKM120) is a potent, orally available, pan-class I PI3K inhibitor developed to target this pathway [1][2]. It has been extensively evaluated in preclinical models and clinical trials across various solid tumors, with a significant focus on advanced and metastatic breast cancer [2][8].
2. Pharmacological Activity
Buparlisib has demonstrated significant pharmacological activity in both preclinical and clinical settings, particularly when used in combination regimens. In preclinical models, buparlisib induced cell death and cell cycle arrest, and showed synergistic growth inhibitory activity when combined with anti-HER2 agents and chemotherapy [2][4].
Clinically, buparlisib monotherapy showed modest efficacy, prompting its evaluation in combination therapies [2]. In HR+/HER2- metastatic breast cancer, the pivotal Phase III BELLE-2 trial evaluated buparlisib plus fulvestrant in postmenopausal women who progressed on aromatase inhibitors. The combination significantly improved median progression-free survival (PFS) compared to placebo plus fulvestrant (6.9 vs. 5.0 months) [2][9]. This benefit was even more pronounced in patients with PIK3CA mutations (7.0 vs. 3.2 months) [9][10]. Similarly, the Phase III BELLE-3 trial demonstrated that buparlisib plus fulvestrant improved PFS (3.9 vs. 1.8 months) in patients who had progressed on prior mTOR inhibitors (e.g., everolimus), providing proof-of-principle that upstream PI3K inhibition can overcome mTOR inhibitor resistance [1][10][11].
In HER2+ breast cancer, buparlisib was investigated in combination with trastuzumab and paclitaxel (NeoPHOEBE trial) and lapatinib (PIKHER2 trial). While the PIKHER2 trial showed a disease control rate of 79% in heavily pretreated, trastuzumab-resistant patients [1][2], the NeoPHOEBE trial was halted early due to severe liver toxicity [2]. Furthermore, the Phase III BELLE-4 trial evaluating buparlisib plus paclitaxel in HER2-negative breast cancer was stopped for futility, as the addition of buparlisib did not improve PFS and increased adverse events [1][2].
3. Molecular Mechanism of Action
Buparlisib is a highly specific, orally bioavailable small molecule inhibitor that targets all four isoforms of class I PI3K (p110α, p110β, p110γ, and p110δ) [1][4]. It functions in an ATP-competitive manner, binding to the catalytic subunits of the PI3K enzyme [1][5]. By inhibiting PI3K, buparlisib prevents the phosphorylation of phosphatidylinositol to the secondary messenger phosphatidylinositol (3,4,5)-trisphosphate (PIP3) [1][2]. The depletion of PIP3 subsequently blocks the activation of downstream serine-threonine kinases, most notably AKT and mTOR [1]. This disruption of the PI3K/AKT/mTOR signaling cascade ultimately inhibits tumor cell growth, proliferation, and survival in susceptible cancer cell populations [1][5]. Additionally, at high concentrations, buparlisib has been reported to interfere with microtubule assembly, inducing cell cycle arrest at the G2-M phase, although this mechanism may be independent of PI3K inhibition and might not occur at standard clinical doses [2][8].
4. Structure-Activity Relationship (SAR)
While detailed chemical structure-activity relationship (SAR) mapping is limited in the provided literature, key structural and pharmacokinetic properties of buparlisib (BKM120) are highlighted. Buparlisib is a pan-class I PI3K inhibitor, meaning its structural conformation allows it to effectively bind the ATP-binding pockets of all class I PI3K isoforms (α, β, δ, γ) without distinguishing between wild-type and mutant forms (such as PIK3CA mutations) [1][4]. A critical pharmacokinetic feature of buparlisib's structure is its ability to penetrate the blood-brain barrier (CNS penetration) [6][9]. While this property provides a theoretical advantage for treating brain metastases (such as in glioblastoma or breast cancer brain metastases) [6], it is also directly responsible for the severe psychiatric adverse events observed in clinical trials [9].
5. Current Limitations
The clinical development of buparlisib has been severely hindered by its narrow therapeutic index and substantial toxicity profile. In major Phase III trials (BELLE-2 and BELLE-3), buparlisib was associated with a high incidence of grade 3/4 adverse events [9][10]. The most common severe toxicities included significant hepatotoxicity (elevated alanine aminotransferase [ALT] and aspartate aminotransferase [AST]), hyperglycemia, rash, fatigue, and gastrointestinal issues (nausea, diarrhea) [1][2][4].
Crucially, due to its CNS penetration, buparlisib caused severe psychiatric side effects, including depression, anxiety, and rare instances of suicidal ideation [9][11]. These adverse events led to high rates of premature treatment discontinuation and dose reductions, resulting in very short treatment exposure (e.g., a median of 1.9 months in BELLE-2) [9]. Furthermore, the lack of selectivity for the mutated PI3Kα isoform means that buparlisib inhibits wild-type PI3K in healthy tissues, exacerbating systemic toxicities like hyperglycemia and limiting the ability to achieve optimal dosing for efficacy [10].
6. Future Perspectives
The challenges encountered with buparlisib have shaped the future trajectory of PI3K inhibitors in breast cancer. Because pan-PI3K inhibition is associated with prohibitive toxicity, the field has shifted towards the development of isoform-specific inhibitors, such as the PI3Kα-selective inhibitor alpelisib (BYL719) and the beta-sparing inhibitor taselisib [2][9][10]. These agents aim to provide a wider therapeutic window and improved tolerability for patients with PIK3CA-mutated tumors.
Future strategies also emphasize the importance of robust patient stratification using predictive biomarkers. Detecting PIK3CA mutations via tumor tissue or circulating tumor DNA (ctDNA) is now recognized as essential for identifying patients most likely to benefit from PI3K targeted therapies [9][11]. Additionally, ongoing research is exploring novel combination strategies to overcome resistance mechanisms. For instance, combining PI3K inhibitors with PARP inhibitors (e.g., olaparib) is being investigated to exploit synthetic lethality and enhance DNA damage in both BRCA-mutated and wild-type cancers [12]. Other combinations with CDK4/6 inhibitors, MEK inhibitors, and immunotherapies are also under active investigation to provide more durable responses in advanced breast cancer [1][2][12].
